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The presently-disclosed subject matter includes thermophilic 
glucan phosphatase polypeptides. In some embodiments the 
polypeptide includes non-native laforin polypeptides, or frag-
ments and/or variants thereof, and in some instances the 
polypeptide can alter the biophysical properties of starch in 
vitro or in planta. The presently-disclosed subject matter also 
includes isolated polynucleotides encoding the present 
polypeptides, methods for processing starch by exposing 
starch to the present polypeptides, and methods for making 
the present polypeptides. 
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1 
THERMOPHILIC PHOSPHATASES AND 
METHODS FOR PROCESSING STARCH 
USING THE SAME 
RELATED APPLICATION 
This application claims priority from U.S. Provisional 
Patent Application No. 61/825,440, filed May 20, 2013, the 
entire disclosure of which is incorporated herein by this ref-
erence. 
GOVERNMENT INTEREST 
2 
(1) 
This invention was made with government support under 
Grant Number R01NS070899 awarded the National Insti-
tutes of Health and Grant Number MCB1252345 awarded by 
theN ational Science Foundation. The government has certain 
rights in the invention. 
TECHNICAL FIELD 
OOHOb~H O ~H 0 
OH 0 HO 
OH 0 HO 
OHoH 
n 
Therefore, to utilize starch for subsequent processing, 
starch-based feedstocks are generated by a three-phase 
approach that utilizes physical, chemical, and enzymatic 
modification (FIG. 1). The physical modification produces 
The presently-disclosed subject matter relates to proteins 25 
such as glucan phosphatases and methods of using the same to 
process starch. In particular, embodiments of the presently-
disclosed subject matter relate to thermophilic phosphatase as 
well as methods for processing starch utilizing at least a 
thermophilic phosphatase and an amylase. 
30 high energy costs due to both milling the material and cycli-
cally modulating the temperature between 50° C. to over 100° 
C. to liquefy starch. In addition to physical modification, 
large amounts of acids and bases are utilized to increase 
enzymatic accessibility. Large quantities of these chemicals INTRODUCTION 
Starch is an important compound for many different pur-
poses, including for food sources, beverages, the manufacture 
of plastics, energy sources such as biofuels, industrial feed-
stocks, and so forth. For instance, starch from the seeds of 
35 are costly to purchase and companies also incur the cost of 
disposing the hazardous waste. Finally, these processes 
require relatively large amounts of recombinant a-amylase, 
which cleave a-1,4-glycosidic linkages, to convert the com-
cereal crops and the tubers of potatoes and cassava accounts 40 
for 50-80% of daily caloric intake. In the United States, over 
20% of com starch is converted into ethanol for use as a 
renewable biofuel, and starch also plays a central role in the 
production of molecular hydrogen by some micro algae and 
plex sugar into fermentable glucose in these. 
Over the last 25 years others have attempted to optimize 
a-amylase catalytic efficiency, thermostability, and pH toler-
ance to increase starch processing techniques. These efforts 
utilize a three-tiered approach of exploiting a-amylases' bio-
logical diversity, structure/function analysis, and directed 
in algal oil production. Microalgal oil production is increased 
by supplying starch to the microalgae so that they grow mix-
otrophically rather than autotrophically. Starch is also a cheap 
and renewable industrial feedstock for producing paper, tex-
tiles, adhesives, plastics, and pharmaceuticals. 
45 evolution. Despite advances in increased catalytic efficiency 
as well as heat and pH tolerance, the amylases are still unable 
to degrade starch without mechanical and chemical assis-
tance. Thus, generating starch-feedstocks using known tech-
Starch is comprised of amylose and amylopectin, which 
are both glucose polymers. Amylose, the minor component, is 
50 niques still results in high costs and environmental concerns 
related to feedstock chemical treatments. 
a linear molecule comprised of glucose moieties linked 
together by a-1,4-glycosidic bonds with very few branches. 
Amylopectin, the major component, is comprised of glucose 55 
linked together by a-1 ,4-glycosidic bonds with a-1 ,6-glyco-
sidic branches occurring every 12-25 glucose moieties. The 
branches in amylopectin are arranged in clusters at regular 
intervals, resulting in a tree-like pattern. Within the clusters, 
adjacent glucose chains form double helices and the clusters 60 
organize into crystalline lamellae. The crystalline lamellae 
make amylopectin, and thus starch, water-insoluble. This 
insolubility renders the surface of starch inaccessible to most 
enzymes, including the amylases that can break it down for 65 
processing. The structures of amylopectin ( 1) and amy lase (2) 
are shown below. 
Hence, there remains a need for compositions and methods 
for processing starch that are relatively less expensive, more 
efficient, and present fewer environmental concerns than 
known compositions and methods. 
BRIEF DESCRIPTION OF THE SEQUENCE 
LISTING 
The following is a brief description of the Sequence Listing 
that is attached hereto and is hereby incorporated by reference 
in its entirety. 
SEQ ID NO: 1 is a nucleic acid sequence encoding a 
Cyanidioschyzon merolae laforin polypeptide of SEQ ID NO: 
2; 
SEQ ID NO: 2 is an amino acid sequence encoding a 
Cyanidioschyzon merolae laforin polypeptide; 
US 9,222,114 B1 
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SEQ ID NO: 3 is a nucleic acid sequence encoding a 
Cyanidioschyzon merolae laforin polypeptide fragment of 
SEQIDNO: 4; 
SEQ ID NO: 4 is an amino acid sequence encoding a 
Cyanidioschyzon merolae laforin polypeptide fragment. 
SEQ ID NO: 5 is a nucleic acid sequence encoding a 
Cyanidioschyzon merolae laforin polypeptide fragment of 
SEQIDNO: 6; 
4 
The present invention relates to novel, unique enzymes 
(i.e., polypeptides) for processing starch. Processing starch 
can include physically modifying the structure of a starch, 
and in certain instances includes degrading the starch. The 
polypeptides disclosed herein can also alter the biophysical 
properties of starch and/or total biomass starch production. 
For example, some embodiments of the present polypeptides 
can increase total biomass starch production and/or degrade 
starch in vitro, in planta, or both. SEQ ID NO: 6 is an amino acid sequence encoding a 
Cyanidioschyzon merolae laforin polypeptide fragment. 10 As used herein, the term "starch" is given its ordinary 
meaning in the art. In this regard, starches are heterogeneous, 
and their physicochemical properties, composition with 
respect to amylose versus amylopectin, amount of phospho-
rylation, and molecular structure all can vary greatly depend-
SEQ ID NO: 7 is a nucleic acid sequence encoding a 
Cyanidioschyzon merolae laforin polypeptide fragment of 
SEQIDNO: 8; 
SEQ ID NO: 8 is an amino acid sequence encoding a 
Cyanidioschyzon merolae laforin polypeptide fragment. 
SEQ ID NO: 9 is a nucleic acid sequence encoding a 
Cyanidioschyzon merolae laforin polypeptide fragment of 
SEQ ID NO: 10; 
15 ing on the source of the starch. These properties can also 
affect starch gelatinization and viscosity, and thus impact 
starch processing. Exemplary starch sources include, but are 
not limited to, Arabidopsis, potato, corn, cassava, rice, wheat, 
and the like. 
SEQ ID NO: 10 is an amino acid sequence encoding a 20 
Cyanidioschyzon merolae laforin polypeptide fragment. 
As used herein, the terms "polypeptide", "protein", and 
"peptide", which are used interchangeably herein, refer to a 
polymer of the protein amino acids, or amino acid analogs, 
regardless of its size or function. Although "protein" is often 
used in reference to relatively large polypeptides, and "pep-
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 includes a schematic showing a conventional 
method for processing starch compared to a plant-based 
starch processing method. 
FIG. 2 includes a schematic showing the sequences of the 
phosphatases of SEQ ID NOS: 2, 4, 6, 8, and 10 as well as 
human laforin, SEX4, and LSF2. 
FIG. 3 includes a plot showing the results of a glucan 
phosphatase assay performed with human, Cyaniioschyzon 
merolae (C. merolae ), chicken, rat, and mouse laforin. 
FIG. 4 includes Coomassie stained protein gel images 
showing the expression and purification of different C. mero-
lae laforin (Cm-laforin) fragments from E. coli. 
FIG. SA includes a plot showing Cm-laforin phosphatase 
activity utilizing a non-biologically relevant substrate pNPP 
over a range from about 37° C. to about 75° C. 
25 tide" is often used in reference to small polypeptides, usage of 
these terms in the art overlaps and varies. The term "polypep-
tide" as used herein refers to peptides, polypeptides, and 
proteins, unless otherwise noted. The terms "protein", 
"polypeptide", and "peptide" are used interchangeably herein 
30 when referring to a gene product. Thus, exemplary polypep-
tides include gene products, naturally occurring proteins, 
homologs, orthologs, paralogs, fragments and other equiva-
lents, variants, and analogs of the foregoing. 
In some embodiments the presently-disclosed polypep-
35 tides include thermophilic phosphatases and/or thermophilic 
glucan phosphatases. Glucan phosphatases dephosphorylate 
glucans in starch metabolism. In some instances, glucan 
phosphatases dephosphorylate glucans so that starch can be 
completely degraded by amylases. 
FIG. SB includes a plot showing Cm-laforin phosphatase 40 
activity from about 3.0 pH to about 8.0 pH. 
In some embodiments the polypeptide is a laforin polypep-
tide, or a fragment and/or variant thereof. In some embodi-
ments the laforin polypeptide can be a vertebrate laforin or a 
vertebrate laforin ortholog. Exemplary vertebrate laforin 
orthologs can include about 85%, about 90%, or about 95% 
FIG. SC includes a plot showing SEX phosphatase activity 
utilizing a non-biologically relevant substrate pNPP over a 
range from about 37° C. to about 75° C. 
FIG. SD includes a plot showing SEX4 phosphatase activ-
ity from about 3.0 pH to about 8.0 pH. 
FIG. SE includes a plot showing the efficiency with which 
Cm -laforin and Hs-laforin can remove phosphate from the C3 
and C6 positions of a glucose ring. 
FIG. 6 includes a plot showing that Cm-laforin increases 
the degradation of starch via amylases (BAM3 and ISA3) in 
the presence of the kinase GWD. 
DETAILED DESCRIPTION OF EXEMPLARY 
EMBODIMENTS 
The details of one or more embodiments of the presently-
disclosed subject matter are set forth in this document. Modi-
fications to embodiments described in this document, and 
other embodiments, will be evident to those of ordinary skill 
in the art after a study of the information provided in this 
document. The information provided in this document, and 
particularly the specific details of the described exemplary 
embodiments, is provided primarily for clearness of under-
standing and no unnecessary limitations are to be understood 
therefrom. In case of conflict, the specification of this docu-
ment, including definitions, will control. 
45 similarity with other vertebrate laforin at the amino acid level. 
Furthermore, in some embodiments the polypeptide includes 
a protozoan laforin, or a fragment and/or variant thereof. The 
laforin can be based on laforin obtained from protozoa 
including, but not limited to, tetrahymena thermophile, Eime-
50 ria tenella, Toxoplasma gondii, Paramecium tetraurelia, 
Neospora caninum, and Cyanidioschyzon merolae. Exem-
plary protozoan laforin orthologs can include about 20% or 
more, about 25% or more, about 30% or more, or about 35% 
or more similarity with Homo sapien laforin (Hs-laforin) at 
55 the amino acid level. 
Certain plant species, such as single-cell algae Cyanid-
ioschyzon merolae (C. merolae), include thermophilic 
polypeptides (thermophile) that can process and degrade 
native starch nnder harsh temperatures and extreme pH con-
60 ditions in. For instance, C. merolae lives in acidic environ-
ments at temperatures of about 50 to about 75° C., living in 
and aronnd thermal vents. The present inventors have found 
that C. merolae includes laforin (hereinafter "Cm-laforin") 
polypeptides that can enhance starch degradation by amy-
65 lases and allow amylases to release more glucose. A full 
length native wild-type protein sequence for Cm-laforin is 
included herein (SEQ ID NO: 2). Embodiments of the pres-
US 9,222,114 B1 
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ently-disclosed polypeptides include isolated and/or non-
naturally occurring fragments and/or variants of wild-type 
laforin. 
Accordingly, in some embodiments the polypeptide is a 
thermophile. The term "thermophile" herein refers to charac- 5 
teristic of operating normally (i.e., is stable) at least at tem-
peratures above about 40° C. In some embodiments the ther-
mophile can operate at temperatures between about 40° C. 
and about 85° C. For example, a "thermophilic polypeptide," 
"thermophile," or and the like refer to a polypeptide that can 10 
function at least at temperatures above about 40° C., and a 
"thermophilic organism" is an organism that can function at 
least at temperatures above about 40° C. Some thermophiles 
can also be stable at relatively lower temperatures. For 
instance, some exemplary Cm-laforin polypeptides are stable 15 
at temperatures of about 10° C. to about 75° C. 
Additionally, in some embodiments the polypeptide can be 
stable at non-neutral pH. In some embodiments the polypep-
tide can be stable at about 3.0 pH to about 8.0 pH. In specific 
embodiments the polypeptide can be stable at about 3.0 pH, 20 
4.0 pH, 5.0 pH, 6.0 pH, 7.0 pH, or 8.0 pH. 
In some embodiments the polypeptide is a fragment of the 
polypeptide including the sequence of SEQ ID NO: 2. The 
terms "polypeptide fragment" or "fragment", when used in 
reference to a reference polypeptide, refers to a polypeptide in 25 
which amino acid residues are deleted as compared to the 
reference polypeptide itself, but where the remaining amino 
acid sequence is usually identical to the corresponding posi-
tions in the reference polypeptide. Such deletions can occur at 
the amino-terminus, carboxy-terminus of the reference 30 
polypeptide, or alternatively both. A fragment can also be a 
"functional fragment," in which case the fragment retains 
some or all of the activity of the reference polypeptide as 
described herein. 
6 
different from the reference polypeptide by one or more 
amino acids, e.g., one or more amino acid substitutions. For 
example a glucan phosphate polypeptide variant differs from 
wild-type glucan phosphatase by one or more amino acid 
substitutions, i.e., mutations. In this regard, polypeptide vari-
ants comprising combinations of two or more mutations can 
respectively be referred to as double mutants, triple mutants, 
and so forth. It will be recognized that certain mutations can 
result in a notable change in function of a polypeptide, while 
other mutations will result in little to no notable change in 
function of the polypeptide. 
In some embodiment the present polypeptides include con-
stituents that share at least 75% homology with a wild type 
polypeptide. In some embodiments the polypeptides share at 
least 85% homology with the wild type polypeptide. In some 
embodiments the polypeptides share at least 90% homology 
with the wild type polypeptide. In some embodiments the 
polypeptides share at least 95% homology with the wild type 
polypeptide. The wild type polypeptide can include the non-
native Cm-laforin polypeptide having the sequence of SEQ 
IDNO: 2. 
"Percent identity," or "percent homology" when used 
herein to describe to an amino acid sequence or a nucleic acid 
sequence, relative to a reference sequence, can be determined 
using the formula described by Karlin and Altschul (Proc. 
Nat!. Acad. Sci. USA 87: 2264-2268, 1990, modified as in 
Proc. Nat!. Acad. Sci. USA 90:5873-5877, 1993). Such a 
formula is incorporated into the basic local alignment search 
tool (BLAST) programs of Altschul eta!. (J. Mol. Bioi. 215: 
403-410, 1990). [BLAST nucleotide searches are performed 
with the NBLAST program, score+100, wordlength=12, to 
obtain nucleotide sequences homologous to a nucleic acid 
molecule of the invention. BLAST protein searches are per-
formed with the XBLAST program, score=50, word 
35 length=3, to obtain amino acid sequences homologous to a 
reference polypeptide (e.g., SEQ ID NO: X). To obtain 
gapped alignments for comparison purposes, Gapped 
BLAST is utilized as described in Altschul, et a!. (Nucleic 
Acids Res. 25: 3389-3402, 1997). When utilizing BLAST 
In some embodiments the polypeptide can comprise the 
sequence of SEQ ID NO: 2 and can include about 267, 268, 
269,270,271,272,273,274,275,276,277,278,279,280, 
281,282,283,284,285,286,287,288,289,290,291,292, 
293,294,295,296,297,298,299,300,301,302,303,304, 
305,306,307,308,309,310,311,312,313,314,315,316, 
317,318,319,320,321,322,323,324,325,326,327,328, 
329,330,331,332,333,334,335,336,337,338,339,340, 
341,342,343,344,345,346,347,348,349,350,351,352, 
353,354,355,356,357,358,359,360,361,362,363,364, 
365,366,367,368,369,370,371,372,373,374,375,376, 45 
377,378,379,380,381,382,383,384,385,386,387,388, 
389,390,391,392,393,394,395,396,397,398,399,400, 
401,402,403,404,405,406,407,408,409,410,411,412, 
413,414,415,416,417,418,419,420,421,422,423,424, 
425,426,427,428,429,430,431,432,433,434,435,436, 
437,438,439,440,441,442,443,444,445,446,447,448, 
449,450,451,452,453,454,455,456,457,458,459,460, 
461,462,463,464,465,466,467,468,469,470,471,472, 
473,474,475,476,477,478,479,480,481,482,483,484, 
485,486,487,488,489,490,491,492,493,494,495,496, 
497,498,499,500,501,502,503,504,505,506,507,508, 
509, 510,511,512, 513, 514,515, 516, 517,518, 519, 520, 
521, 522, 523, 524, 525, 526, 527, 528, 529, 530, or 531 
amino acid residues. In specific embodiments the polypeptide 
fragments include about 1 to about 266 amino acid residues 
deleted from theN-terminus of the polypeptide, including 
polypeptide fragments having about 1 to about 266 amino 
acid residues deleted from theN-terminus immediately fol-
lowing the start methionine (M) amino acid. 
As described herein, the presently disclosed subject matter 
also include variants of the presently-disclosed polypeptides. 
The term "variant" refers to an amino acid sequence that is 
40 and Gapped BLAST programs, the default parameters of the 
respective programs (e.g., XBLAST and NBLAST) are used. 
See http://www.ncbi.nlm.nik.gov, and reference is made to 
the most recent version of the programs that are available as of 
Jul. 19, 2012. 
In one embodiment the polypeptide comprises the 
sequence of SEQ ID NO: 4. In another embodiment the 
polypeptide comprises a fragment, a variant, or both a frag-
ment and variant of SEQ ID NO: 4. In another embodiment 
the polypeptide comprises the sequence of SEQ ID NO: 6. In 
50 another embodiment the polypeptide comprises a fragment, a 
variant, or both a fragment and variant of SEQ ID NO: 6. In 
another embodiment the polypeptide comprises the sequence 
of SEQ ID NO: 8. In another embodiment the polypeptide 
comprises a fragment, a variant, or both a fragment and vari-
55 ant of SEQ ID NO: 8. In another embodiment the polypeptide 
comprises the sequence of SEQ ID NO: 10. In another 
embodiment the polypeptide comprises a fragment, a variant, 
or both a fragment and variant of SEQ ID NO: 10. 
The presently-disclosed subject matter also includes iso-
60 lated polynucleotides that encode any of the presently-dis-
closed polypeptides. The terms "nucleotide," "polynucle-
otide," "nucleic acid," and "nucleic acid sequence" refer to 
deoxyribonucleotides or ribonucleotides and polymers 
thereof in either single or double stranded form. Unless spe-
65 cifically limited, the term encompasses nucleic acids contain-
ing known analogues of natural nucleotides that have similar 
binding properties as the reference nucleic acid and are 
US 9,222,114 B1 
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metabolized in a manner similar to naturally occurring nucle-
otides. The terms also include compounds only comprising 
the coding regions, or exons, of a particular DNA sequence. 
The terms are therefore inclusive of eDNA molecules. 
The term "isolated", when used in the context of an isolated 
polynucleotide or an isolated polypeptide, is a polynucleotide 
8 
acid, and therefore the term polynucleotide specifically 
includes complementary DNA as used herein. 
In some embodiments the polynucleotide includes the 
nucleotide sequence of SEQ ID NO: 3. In some embodiments 
the polynucleotide includes the nucleotide sequence of SEQ 
ID NO: 5. In some embodiments the polynucleotide includes 
the nucleotide sequence of SEQ ID NO: 7. In some embodi-
ments the polynucleotide includes the nucleotide sequence of 
SEQ ID NO: 9. 
The presently-disclosed subject matter further includes a 
composition comprising starch, wherein the starch is from a 
plant expressing one of the polypeptides described herein. In 
some embodiments the polypeptide includes a thermophilic 
glucan phosphatase polypeptide. In some embodiments the 
or polypeptide that, by the hand of man, exists apart from its 
native environment and is therefore not a product of nature. 
An isolated polynucleotide or polypeptide can exist in a puri-
fied form or can exist in a non-native environment such as, for 10 
example, in a transgenic host cell. Unless otherwise indi-
cated, all polypeptides and polynucleotides described herein 
include isolated forms thereof even where not explicitly 
recited. Thus, unless stated otherwise, all the polypeptide and 
polynucleotide described herein can be modified by the term 
isolated. 
15 polypeptides includes a laforin polypeptide, such as a Cm-
laforin polypeptide. As discussed herein, organisms express-
ing the present polypeptides can produce starch with altered 
biophysical properties, which can be beneficial for manufac-
turing processes in various industries, including food, bever-
In some embodiments the polynucleotides encode a ther-
mophilic phosphatase, laforin polypeptide, and/or a 
Cm-laforin polypeptide. In other embodiments the poly-
nucleotide includes the sequence of SEQ ID NO: 1, and the 
polynucleotide encodes the polypeptide including the 
sequence of SEQ ID NO: 2. In other embodiments the poly-
nucleotide encodes a fragment and/or a variant of the 
polypeptide including the sequence of SEQ ID NO: 2. 
As before, the term "polynucleotide fragment" or the like 
can refer to a polynucleotide in which nucleic acids are 
deleted as compared to the reference polynucleotide itself, 
but where the remaining nucleic acid sequence is usually 
identical to the corresponding positions in the reference poly-
nucleotide. Such deletions can occur at any location of the 
sequence. In some embodiments the polynucleotide includes 
a fragment of the isolated polynucleotide having the sequence 
of SEQ ID NO: 1. In some embodiments the polynucleotide 
fragment includes about 800, 900, 1000, 1100, 1200, 1300, 
1400, 1500, or more nucleotides, and in some embodiments 
the polynucleotide fragment includes about 801 to about 
1596 nucleotides. 
The term "variant" in reference to a polynucleotide can 
refer to a polynucleotide that is different from the reference 
polynucleotide by one or more nucleic acids. In this regard, 
some polynucleotide variants have been codon optimized 
relative to a reference polynucleotide, and the polynucleotide 
variant can produce polypeptide more effectively in certain 
organisms relative to the reference polynucleotide. For 
instance, in some embodiments a polynucleotide that 
includes the sequence of SEQ ID NOS: 3, 4, 5, or 9 expresses, 
respectively, a polypeptide that includes the sequence of SEQ 
ID NOS: 4, 6, 8, or 10 more effectively (e.g., higher purity) in 
20 age, confectionary, plastic, paper, building, energy, textile, 
agriculture, and pharmaceutical industries. 
The presently-disclosed subject matter further includes 
methods for processing starch, wherein processing can 
include degrading starch to smaller polysaccharides and/or 
25 monosaccharides. In some embodiments the methods for pro-
cessing starch comprise providing a starch, exposing the 
starch to a thermophilic glucan phosphatase, and collecting 
the starch that has been exposed to the thermophilic glucan 
phosphatase. In some embodiments the present polypeptides 
30 can be used in a method for processing starch that does not 
require harsh acids and harsh bases. Thus, the present meth-
ods can be more cost-effective and have a smaller environ-
mental impact relative to known methods. 
The term "providing" as used herein to refer to delivering, 
35 obtaining, procuring, or the like a substance. For instance, a 
polypeptide, a starch, or both can be provided by any means. 
In some embodiments the polypeptide is provided in an iso-
lated form that can be exposed directly to a starch. In other 
embodiments an organism expresses the polypeptide, and the 
40 polypeptide is thereby provided by the organism. Likewise, 
starch can be provided by itself or can be provided within a 
plant. 
In some embodiments the exposing step occurs within a 
plant. That is, a plant can express a thermophilic glucan 
45 phosphatase, and the thermophilic glucan phosphatase can be 
exposed to starch within the plant. On the other hand, in 
industrial applications a thermophilic glucan phosphatase 
can be provided in an isolated form, and can be exposed to a 
starch by mixing the two components in a container. 
The term "collecting" is used herein to refer to any process 
or method where starch is used, obtained, cultivated, 
ingested, or the like. For example, in some embodiments 
starch is collected by harvesting a plant that comprises starch 
and processing the plant in order to obtain starch or other 
E. coli cells when compared to the polynucleotide having the 50 
sequence of SEQ ID NO: 1. In this respect, a polynucleotide 
variant can have a different sequence than a reference poly-
nucleotide without necessarily expressing a polypeptide that 
includes amino acid mutations relative to the reference 
polypeptide. 55 sugars derived therefrom. In some embodiments, collecting 
refers to ingesting a plant that comprises a thermophilic glu-
can phosphatase. In other embodiments collecting refers to 
collecting starch that has been processed in a container with a 
thermophilic glucan phosphatase. 
The presently-described starch processing methods do not 
suffer from the inability of amylases to access starch's water 
insoluble surface. Amylases degrade starch to maltose and 
glucose, but despite industry's 25 years of optimizing amy-
lase to work under extreme conditions, amylase cannot 
Unless otherwise indicated, a particular nucleic acid 
sequence also implicitly encompasses conservatively modi-
fied versions thereof (e.g., degenerate codon substitutions) 
and complementary sequences and as well as the sequence 
explicitly indicated. Specifically, degenerate codon substitu- 60 
tions can be achieved by generating sequences in which the 
third position of one or more selected (or all) codons is sub-
stituted with mixed base and/or deoxyinosine residues 
(Batzer eta!. (1991) Nucleic Acid Res 19:5081; Ohtsuka eta!. 
(1985) J Bioi Chern 260:2605 2608; Rossolini eta!. (1994) 
Mol Cell Probes 8:91 98). Thus, the term polynucleotide 
includes both deoxyribonucleic acid (DNA) and ribonucleic 
65 degrade its own starch. In order to solubilize starch and to 
make it accessible to amylase, milling, extreme heat and acids 
and bases are required. One recent improved method for 
US 9,222,114 B1 
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processing starch is described in U.S. Provisional patent 
application Ser. No. 13/928,160, which is incorporated herein 
by reference, and which describes non-thermophilic glucan 
phosphatase variants for starch dephosphorylation. 
10 
gathered at various times during the course of development 
and experimentation related to the presently-disclosed sub-
ject matter. 
Example 1 
This Example describes the identification, cloning strate-
gies, and purification of Cm-laforin polypeptides. 
Laforin genes were identified in six protozoan genomes: 
Tetrahymena thermophile, Eimeria tenella, Toxoplasma gon-
dii, Paramecium tetraurelia, Neospora caninum, and Cyan-
idioschyzon merolae. While the vertebrate laforin orthologs 
are similar, the protozoan laforin orthologs are about 20% to 
about 35% identical to Hs-laforin. Furthermore, some of 
However, in order to overcome problems in the art, the 
present inventors discovered that use of the present polypep-
tides allows the starch to be processed without the milling and 
chemical treatments that are typically required. Thus, in some 
instances the present polypeptides can make a starch acces-
sible to amylases for processing. The present methods can 10 
utilize polypeptides that include a thermophilic glucan phos-
phatase, such as laforin and the like. In specific embodiments 
the thermophilic glucan phosphatase includes the sequence of 
SEQ ID NO: 2, or a fragment and/or variant thereof. 
Some methods further comprise exposing the starch to a 
kinase, an amylase, or both before the collecting step. Some 
embodied methods comprise a three-step exposing step 
wherein the starch is sequentially exposed to a thermophilic 
phosphatase, a kinase, and an amylase. In some embodied 20 
methods glucan dikinases phosphorylate the outer starch sur-
face and solubilize the outer surface allowing amylases to 
bind and degrade starch, and glucan phosphatases release 
phosphate and reset the cycle so that amylase-directed deg-
radation can continue past the phosphate. Prior to the present 25 
method, no known method used a combination of a thermo-
philic phosphatase, a kinase, and an amylase to process 
starch. Instead, prior to the present invention, harsh acids and 
bases were required to process starches. Accordingly, the 
present methods that use a one or a combination of one or 30 
more different polypeptides are superior to prior know meth-
ods for processing starch. 
15 these organisms live in extreme envirouments and likely have 
enzymes that function under harsh conditions. For example, 
the single-cell red algae C. merolae lives in highly acidic 
environments (i.e., pH<2) at temperatures of about 45° C. to 
about 60° C. 
Five of the protozoan laforin orthologs were cloned to 
identify a laforin ortholog that was amenable to in vitro 
manipulation. To define the optimal constructs for recombi-
nant protein expression, laforin primary sequences were ana-
lyzed from multiple species using a similar strategy that was 
successful for SEX4 (VanderKooi eta!., 201 0). The strategy 
was to predict domain boundaries, secondary structure, 
regions of disorder, and regions of hydrophobicity for the 
polypeptides. Based on these data, the full-length laforin gene 
was cloned as well as multiple fragments (i.e., truncations) 
that remove the amino- and/or carboxy-terminus of the pro-
tein. 
In the case of Cm-laforin, thedata, four Cm-laforin frag-
In some embodiments of the present methods, the polypep-
tides are thermophiles and are capable of functioning under 
extreme conditions. For instance, Cm-laforin maintains its 35 
activity from about 37° C. to about 75° C. and under a wide 
range of pH conditions, including about 3.0 pH to about 8.0 
pH. Additionally, Cm-laforin has a relatively high specific 
activity and is relatively efficient at removing phosphate from 
the C3 and C6 position of starch compared to human laforin. 40 
Lastly, Cm-laforin can increase amylase-directed degrada-
tion of starch. 
ments were cloned into multiple bacterial expression vectors, 
including Met27 (truncates first 26 amino acids), a codon 
optimized for Ser157, a codon optimized for Gly258, and a 
codon optimized for Arg267. Cm-laforin proteins that were 
over 99% pure were expressed and purified were produced by 
tranforming BL21-CodonPlus Escherichia coli cells (Strat-
agene, La Jolla, Calif.) with expression vector. Cells were 
grown at 37° C. in 2xYT to an O.D.600 of0.6-0.8, placed in 
ice for 20 minutes, were induced with 1 mM isopropyl ~-D-
thiogalactoside (IPTG), were grown at 16° C. for about 16 
hours, and were harvested by centrifugation. Cells were lysed 
in 20 mM Tris-HCl (pH 7.5), 100 mM NaCl, and 2 mM 
The presently-disclosed subject matter also includes meth-
ods for making an isolated polypeptide. In some embodi-
ments the method comprises providing a cell that includes at 
least one of the presently-described polynucleotides, cultur-
ing the cell under conditions that permit the cell to produce a 
polypeptide encoded by the polynucleotide, and collecting 
the polypeptide. The cell can naturally include the polynucle-
otide or the polynucleotide can be introduced to the cell by 
known methods. For instance, a vector can be utilized to 
introduce an embodiment of the present polynucleotides to 
the cell. 
The cell is not particularly limited except that it must be 
capable of producing the polypeptide encoded by the poly-
nucleotide. In some embodiments the polynucleotides can be 
sequence optimized for the production of a polypeptide in a 
particular cell, such as E. coli cells. The polypeptide produced 
by the cell can be collected by known means, thereby provid-
ing the isolated polypeptide. 
EXAMPLES 
The presently -disclosed subject matter is further illustrated 
by the following specific but non-limiting examples. Some 
examples are prophetic. Some of the following examples may 
include compilations of data that are representative of data 
45 dithiothreitol (DTT), centrifuged, and the proteins were puri-
fied using a Profinia IMAC column with Ni2+ beads (Bio-
Rad, Hercules, Calif.) with a Profinia protein purification 
system (Bio-Rad). Polypeptides were eluted in lysis buffer 
containing 300 mM imidazole. Lastly, polypeptide was puri-
50 fied to homogeneity using a HiLoad 26/60 Superdex 200 size 
exclusion column (General Electric, Schenectady, N.Y.) 
(FIG. 4). 
About 25 mg of soluble Cm-laforin per liter of E. coli cells 
was purified. The Cm-laforin was capable ofbeing purified to 
55 18 mg/ml, and this polypeptide was stable at 4 o C. for over 1 
week. Given the relatively high purity that was attained, Cm-
laforin was selected for further analysis. 
60 
Example 2 
This Example describes the cloning and identification of 
vertebrate laforin orthologs. 
A total of seven vertebrate laforin orthologs that all 
robustly express in E. coli were identified, but only enough 
65 protein was purified to perform in vitro assays due to protein 
aggregation and precipitation. The vertebrate laforin 
orthologs were more than 85% similar at the amino acid level. 
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To test the glucan phosphatase activity of Cm-laforin, an 
assay based on the complex formation of malachite green 
with phospho-molybdate was implemented to measure inor-
ganic phosphate release. 
The glucan phosphatase assays against amylopectin, as 5 
determined via released free phosphate by malachite green 
detection, were performed as previously described with the 
following modifications (Sherwood, 2013). Reactions were 
performed in 20 f.LL, reactions, containing 1 x phosphatase 
buffer (0.1M sodium acetate, 0.05 M bis-Tris, 0.05 M Tris- 10 
HCl, pH 7 .0, and 2 mM DTT), 100-1000 ng protein, and 45 flg 
amylopectin. Amylopectin was solubilized using the Roach 
method (Wang, 2004 ). The reaction was stopped by the addi-
tion of 20 f.LL, of 100 mM N-ethylmaleamide and 80 f.LL, of 
malachite green reagent. Absorbance was measured at 620 m. 15 
The assay was performed with each protein six times or more 
to determine specific activity. Using this assay, it was found 
that Cm-laforin possessed nearly twice the specific activity of 
human-laforin, rat-laforin, or mouse-laforin (FIG. 3). 
Example 3 
20 
12 
unincorporated 33P had been removed. These products were 
utilized as substrates in dephosphorylation assays with Cm-
laforin or human laforin. 
In both the C6-33P- and C3-33P-labeleled cases, the starch 
granules were phosphorylated at both positions; however, the 
33P-label was located at only one or the other position. 33P-
~-ATP was obtained from Hartmann Analytic (Braunsch-
weig, Germany). 150 ng of recombinant proteins were incu-
bated in dephosphorylation buffer (100 mM sodium acetate, 
50 mM bis-Tris, 50 mM Tris-HCl, pH 6.5, 0.05% [v/v] Triton 
X-100, 1 fld/flL [w/v] BSA, and 2 mM DTT) with the C6- or 
C3-prelabeled starch ( 4 mg/mL) in a final volume of 150 f.LL 
on a rotating wheel for 5 min at 25° C. The reaction was 
terminated by the addition of 50 f.LL ofl 0% SDS. The reaction 
tubes were then centrifuged at 13,000 rpm for 5 min to pellet 
the starch. 33P release into 150 f.LL of supernatant was deter-
mined using a 1900 TR liquid scintillation counter (Packard 
Elmer, Waltham, Mass.). The assay was performed with each 
protein six times to determine specific activity (FIG. SE). 
Example 5 
This Example describes procedures conducted to charac- This Example describes the Cm-laforin's ability to 
terize the thermophilic activity ofCm-laforin polypeptides. enhance starch degradation to a higher degree than SEX4. 
To observe generic phosphatase activity, a phosphatase 25 Native Arabidopsis starch was treated with combinations 
assay using the exogenous substrate para-nitrophenyl phos- ofBeta-amylase3 (BAM3) (sweet potato, Sigma A7005, St. 
phate (pNPP) was implemented. Most DSPs can cleave Louis, Mo.), isoamylase3 (ISA3) (Pseudomonas sp. Sigma 
pNPP, and this cleavage results in a colorimetric change. 15284), GWD, and SEX4 or Cm-laforin. The total volume of 
Since C. merolae is a thermophile, the phopshatase activity of the assays were 200 ul and consisted of30 mM HEPES-KOH, 
Cm-laforin was observed under a variety of temperatures and 30 pH 7.5, 5 mM MgC12 , 5 mM CaC12 , 1 mMATP, 2.5 mg starch, 
pH conditions. +1-1 ul stock concentration BAM, +1-1.5 ul1:50 stock dilu-
Previously-described phosphatase assays using pNPP tion ISA, +1-4.5 ug GWD, +1-4.5 ug SEX4, and +1-4.5 ug 
were performed with the following modifications (Sherwood, laforin. The samples were incubated for 90 minutes with 
2013; Gentry, 2007). Hydrolysis of pNPP was performed in gentle agitation at room temperature. A 1.5 minute spin at 
50 flL, reactions, containing 1x phosphatase buffer (0.1M 35 15,000 RPM was performed and the supernatant was col-
sodium acetate, 0.05 M bis-Tris, 0.05 M Tris-HCl, and 2 mM lected, followed by another spin at 15,000 RPM for 5 minutes 
DTT) at pH 3-8, 50 mM pNPP, and 1 flg of enzyme at 37-75° to remove any residual starch. Any remaining oligosaccha-
C. for 15 minutes. The reaction was terminated by the addi- rides were hydrolyzed, and glucose content in the supernatant 
tion of 200 f.LL of 0.25 M NaOH, and absorbance was mea- was quantified using the Boehringer Mannheim assay kit 
sured at 410 nm. The assay was performed with each protein 40 (10716251035; Ingelheim am Rhein, Germany) per manu-
six times or more to determine specific activity. facturer's protocol. 
As shown in FIG. SA, Cm-laforin maintained its activity As shown in FIG. 6, ~-amylases (BAM) and isoamylases 
from 37° C.-80° C. In addition, Cm-laforin was active over a (I SA) were responsible for degrading starch into glucose and 
wide array of pH conditions from about 3.0 pH to about 8.0 maltose in planta. Phosphate-free starch was isolated from 
pH (FIG. SB). On the other hand, SEX4 had a significantly 45 gwd/pwd deficient Arabidopsis plants and it was demon-
lower specific activity against pNPP, and SEX4 did not main- strated that the activity of BAM3 and ISA3 are markedly 
tain its activity over a wide-range of temperature or pH con- enhanced in vitro when starch is phosphorylated by the glu-
ditions (FIGS. SC and SD). can dikinase GWD. 
Furthermore, the hydrolysis activity of BAMs and ISA in 
Example 4 
This Example describes procedures that measured the 
position of the phosphate that is released off of glucose within 
starch by Cm-laforin. 
50 combination with GWD was observed in the presence and 
absence of SEX4 and Cm-laforin. The activity ofBAM3 and 
ISA3 increased in the presence of SEX4, and increased fur-
ther in the presence of Cm-laforin (FIG. 6). 
Phosphate release from 33P-lableled starch granules was 55 
performed as previously described with the following varia-
tions (Kotting, 2009). Phosphate-free starch granules were 
isolated from the Arabidopsis sex1-3 mutant. C6-33P-la-
beleled starch was generated by phosphorylating the starch 
with 33P-~-ATP at the C6-position by GWD followed by 60 
washing nntil all unincorporated 33P had been removed, and 
non-radio-labeled ATP was added with PWD to phosphory-
late the C3 position followed by dialyzing and precipitating 
out the ATP and PWD. C3-33P-labeled starch was generated 
by phosphorylating the starch with unlabeled ATP at the 65 
C6-position by GWD followed by phosphorylation with 33P-
~R-ATP at the C3-position by PWD and washing until all 
While the terms used herein are believed to be well under-
stood by one of ordinary skill in the art, the definitions set 
forth herein are provided to facilitate explanation of the pres-
ently-disclosed subject matter. 
Unless defined otherwise, all technical and scientific terms 
used herein have the same meaning as commonly understood 
by one of ordinary skill in the art to which the presently-
disclosed subject matter belongs. Although any methods, 
devices, and materials similar or equivalent to those described 
herein can be used in the practice or testing of the presently-
disclosed subject matter, representative methods, devices, 
and materials are now described. 
Following long-standing patent law convention, the terms 
"a", "an", and "the" refer to "one or more" when used in this 
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application, including the claims. Thus, for example, refer-
ence to "a cell" includes a plurality of such cells, and so forth. 
14 
3. HAKI, eta!, "Developments in industrial important ther-
mostable enzymes: a review", Bioresource Technology, 
vol. 89,2003, pages 17-34. 
4. JOBLING, Steve, "Improving starch for food and indus-
trial applications", Current Opinion in Plant Biology, vol. 
7, 2004, pages 210-218. 
Unless otherwise indicated, all numbers expressing quan-
tities of ingredients, properties such as reaction conditions, 
and so forth used in the specification and claims are to be 
understood as being modified in all instances by the term 
"about". Accordingly, unless indicated to the contrary, the 
numerical parameters set forth in this specification and claims 
are approximations that can vary depending upon the desired 
properties sought to be obtained by the presently-disclosed 
subject matter. 
As used herein, the term "about," when referring to a value 
or to an amount of mass, weight, time, volume, concentration 
or percentage is meant to encompass variations of in some 
embodiments ±50%, in some embodiments ±40%, in some 
embodiments ±30%, in some embodiments ±20%, in some 
embodiments ±10%, in some embodiments ±5%, in some 
embodiments ±1 %, in some embodiments ±0.5%, and in 
some embodiments ±0.1% from the specified amount, as such 
variations are appropriate to perform the disclosed method. 
20 
5. KELLY, eta!, "Stach and a-glucan acting enzymes, modu-
lating their properties by directed evolution", Journal of 
Biotechnology, vol. 140, 2009, pages 184-193. 
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823-835. 
As used herein, ranges can be expressed as from "about" 
one particular value, and/or to "about" another particular 
value. It is also understood that there are a number of values 
disclosed herein, and that each value is also herein disclosed 
as "about" that particular value in addition to the value itself. 
25 For example, if the value "10" is disclosed, then "about 10" is 
also disclosed. It is also understood that each unit between 
two particular units are also disclosed. For example, ifl 0 and 
15 are disclosed, then 11, 12, 13, and 14 are also disclosed. 
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tioned. All such references, including those listed below, are 
incorporated herein by reference. 
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<160> NUMBER OF SEQ ID NOS, 10 
<210> SEQ ID NO 1 
<211> LENGTH, 1599 
<212> TYPE, DNA 
SEQUENCE LISTING 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, C. merolae laforin full-length 
<400> SEQUENCE, 1 
Biochemical and Biophysical Research Communications, 
vol. 325, 2004, pages 726-730. 
atggcgcgta tacgaacatc ggatcgccgg aacacaaacg accaggcagg ctcggaaagc 60 
cggcatcggg tgccgtcgat ggcaagagcg ccagctgctg attcgtctgg tgcgcagtca 120 
acaccagccg cacggcgtgc ttccgaggga gtctctgtag ctgagcctcc gtcaaagcca 180 
gctgctgatt cgtctggtgc gcagtcaaca ccagccgcac ggcgtgcttc cgagggagtc 240 
tctgtagctg ggcctccatc aaagccagct gccgattcgt ctggtgcgca gtcaacacca 300 
gccgcacggt ttgcatccga gggtgtctct gtacctgagc ctccgtcaaa gccagctgct 360 
gattcgtctg gtgcgcagtc aacaccagcc gcacggggtg cttccgagga tatctctgta 420 
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-continued 
cctgggcctc cttcagacat tgcggacacg atctcaaaga atgatcgaag cgtaaccccg 
acgattccga ctttattccg cgtctactgc cacacggagt ttggcgatgc tgtcgtcgcc 
gctggtagtc acgacaaatt gggcaactgg gagcccgcga aagcgctccg gctccgtcat 
caatgccaag tggatacacc gttccgtgac tgctgggaag gcgaggtaga ccttgtaccc 
gaaacaagct tcgagttcaa attcgtgcgt cttataggcg gagatccgca gcgtgcgctc 
tgggaaaccg gacccaaccg aagagccgtg atccagagaa actcgaagga cggctgcctg 
attgaagtgg aatgggagcg tacgcgtgtg ctgttctcaa tatactatcc taccaaagag 
aagcagcatc tctgtgtcac tggcgatctt ccggaaatcg gtcggtgggt agaaccgggt 
ccagtaccca tggccctctc aactactgag gagcgtttgg aaacaggagg caagggccga 
cgttggtcct tgacggtttc agtgccatcc acggtgggca aattcgccta tcgctatgtg 
ctagtcgacg ataaccgcca gcaaacgatc tgggaacgag aaccgaatcg ctatgcaaca 
ctagaacgag cggtgaacgg gcgcctcgaa tgtttcgatg caaattttgt cgcttcgtta 
gaatttgatg aaatatgtcc ggacatttac atagggccct acccacaaac tccagagcat 
gtcgaaatga tgcatgaggc ggggattacg gctgttttga atttacagac cgatgaggac 
tttgcacacc gcagtattcc ctggtcgacg ctgatggaga catatacagc actagagatg 
caagtcatcc gttgtccgat tccggatttt aatgcggagg cgctcatgca gttgcttccg 
gatgccgtac gcgctcttga tgcggcgctc aaggcgaagc gcgtcgtcta cgtgcactgt 
accgcaggaa tgggtcgagc gcccgctgta gttgtcgcct acctcgtgtg gcgccgcggc 
atgacgctgg aggatgcctt gtcgcacgtt aaagcacgtc gtgctgtggc cgcgccgaat 
gtcaccgtat tggaaaaggt tcttcgtaat cccttgtga 
<210> SEQ ID NO 2 
<211> LENGTH, 532 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, C. merolae laforin full-length polypeptide 
<400> SEQUENCE, 2 
Met Ala Arg Ile Arg Thr Ser Asp Arg Arg Asn Thr Asn Asp Gln Ala 
1 5 10 15 
Gly Ser Glu Ser Arg His Arg Val Pro Ser Met Ala Arg Ala Pro Ala 
20 25 30 
Ala Asp Ser Ser Gly Ala Gln Ser Thr Pro Ala Ala Arg Arg Ala Ser 
35 40 45 
Glu Gly Val Ser Val Ala Glu Pro Pro Ser Lys Pro Ala Ala Asp Ser 
50 55 60 
Ser Gly Ala Gln Ser Thr Pro Ala Ala Arg Arg Ala Ser Glu Gly Val 
65 70 75 80 
Ser Val Ala Gly Pro Pro Ser Lys Pro Ala Ala Asp Ser Ser Gly Ala 
85 90 95 
Gln Ser Thr Pro Ala Ala Arg Phe Ala Ser Glu Gly Val Ser Val Pro 
100 105 110 
Glu Pro Pro Ser Lys Pro Ala Ala Asp Ser Ser Gly Ala Gln Ser Thr 
115 120 125 
Pro Ala Ala Arg Gly Ala Ser Glu Asp Ile Ser Val Pro Gly Pro Pro 
130 135 140 
Ser Asp Ile Ala Asp Thr Ile Ser Lys Asn Asp Arg Ser Val Thr Pro 
16 
480 
540 
600 
660 
720 
780 
840 
900 
960 
1020 
1080 
1140 
1200 
1260 
1320 
1380 
1440 
1500 
1560 
1599 
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17 
-continued 
145 150 155 160 
Thr Ile Pro Thr Leu Phe Arg Val Tyr Cys His Thr Glu Phe Gly Asp 
165 170 175 
Ala Val Val Ala Ala Gly Ser His Asp Lys Leu Gly Asn Trp Glu Pro 
180 185 190 
Ala Lys Ala Leu Arg Leu Arg His Gln Cys Gln Val Asp Thr Pro Phe 
195 200 205 
Arg Asp Cys Trp Glu Gly Glu Val Asp Leu Val Pro Glu Thr Ser Phe 
210 215 220 
Glu Phe Lys Phe Val Arg Leu Ile Gly Gly Asp Pro Gln Arg Ala Leu 
225 230 235 240 
Trp Glu Thr Gly Pro Asn Arg Arg Ala Val Ile Gln Arg Asn Ser Lys 
245 250 255 
Asp Gly Cys Leu Ile Glu Val Glu Trp Glu Arg Thr Arg Val Leu Phe 
260 265 270 
Ser Ile Tyr Tyr Pro Thr Lys Glu Lys Gln His Leu Cys Val Thr Gly 
275 280 285 
Asp Leu Pro Glu Ile Gly Arg Trp Val Glu Pro Gly Pro Val Pro Met 
290 295 300 
Ala Leu Ser Thr Thr Glu Glu Arg Leu Glu Thr Gly Gly Lys Gly Arg 
305 310 315 320 
Arg Trp Ser Leu Thr Val Ser Val Pro Ser Thr Val Gly Lys Phe Ala 
325 330 335 
Tyr Arg Tyr Val Leu Val Asp Asp Asn Arg Gln Gln Thr Ile Trp Glu 
340 345 350 
Arg Glu Pro Asn Arg Tyr Ala Thr Leu Glu Arg Ala Val Asn Gly Arg 
355 360 365 
Leu Glu Cys Phe Asp Ala Asn Phe Val Ala Ser Leu Glu Phe Asp Glu 
370 375 380 
Ile Cys Pro Asp Ile Tyr Ile Gly Pro Tyr Pro Gln Thr Pro Glu His 
385 390 395 400 
Val Glu Met Met His Glu Ala Gly Ile Thr Ala Val Leu Asn Leu Gln 
405 410 415 
Thr Asp Glu Asp Phe Ala His Arg Ser Ile Pro Trp Ser Thr Leu Met 
420 425 430 
Glu Thr Tyr Thr Ala Leu Glu Met Gln Val Ile Arg Cys Pro Ile Pro 
435 440 445 
Asp Phe Asn Ala Glu Ala Leu Met Gln Leu Leu Pro Asp Ala Val Arg 
450 455 460 
Ala Leu Asp Ala Ala Leu Lys Ala Lys Arg Val Val Tyr Val His Cys 
465 470 475 480 
Thr Ala Gly Met Gly Arg Ala Pro Ala Val Val Val Ala Tyr Leu Val 
485 490 495 
Trp Arg Arg Gly Met Thr Leu Glu Asp Ala Leu Ser His Val Lys Ala 
500 505 510 
Arg Arg Ala Val Ala Ala Pro Asn Val Thr Val Leu Glu Lys Val Leu 
515 520 525 
Arg Asn Pro Leu 
530 
<210> SEQ ID NO 3 
<211> LENGTH, 1521 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
18 
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19 
-continued 
<220> FEATURE, 
<223> OTHER INFORMATION, C. merolae laforin Met 27 fragment 
<400> SEQUENCE, 3 
atggcaagag cgccagctgc tgattcgtct ggtgcgcagt caacaccagc cgcacggcgt 
gcttccgagg gagtctctgt agctgagcct ccgtcaaagc cagctgctga ttcgtctggt 
gcgcagtcaa caccagccgc acggcgtgct tccgagggag tctctgtagc tgggcctcca 
tcaaagccag ctgccgattc gtctggtgcg cagtcaacac cagccgcacg gtttgcatcc 
gagggtgtct ctgtacctga gcctccgtca aagccagctg ctgattcgtc tggtgcgcag 
tcaacaccag ccgcacgggg tgcttccgag gatatctctg tacctgggcc tccttcagac 
attgcggaca cgatctcaaa gaatgatcga agcgtaaccc cgacgattcc gactttattc 
cgcgtctact gccacacgga gtttggcgat gctgtcgtcg ccgctggtag tcacgacaaa 
ttgggcaact gggagcccgc gaaagcgctc cggctccgtc atcaatgcca agtggataca 
ccgttccgtg actgctggga aggcgaggta gaccttgtac ccgaaacaag cttcgagttc 
aaattcgtgc gtcttatagg cggagatccg cagcgtgcgc tctgggaaac cggacccaac 
cgaagagccg tgatccagag aaactcgaag gacggctgcc tgattgaagt ggaatgggag 
cgtacgcgtg tgctgttctc aatatactat cctaccaaag agaagcagca tctctgtgtc 
actggcgatc ttccggaaat cggtcggtgg gtagaaccgg gtccagtacc catggccctc 
tcaactactg aggagcgttt ggaaacagga ggcaagggcc gacgttggtc cttgacggtt 
tcagtgccat ccacggtggg caaattcgcc tatcgctatg tgctagtcga cgataaccgc 
cagcaaacga tctgggaacg agaaccgaat cgctatgcaa cactagaacg agcggtgaac 
gggcgcctcg aatgtttcga tgcaaatttt gtcgcttcgt tagaatttga tgaaatatgt 
ccggacattt acatagggcc ctacccacaa actccagagc atgtcgaaat gatgcatgag 
gcggggatta cggctgtttt gaatttacag accgatgagg actttgcaca ccgcagtatt 
ccctggtcga cgctgatgga gacatataca gcactagaga tgcaagtcat ccgttgtccg 
attccggatt ttaatgcgga ggcgctcatg cagttgcttc cggatgccgt acgcgctctt 
gatgcggcgc tcaaggcgaa gcgcgtcgtc tacgtgcact gtaccgcagg aatgggtcga 
gcgcccgctg tagttgtcgc ctacctcgtg tggcgccgcg gcatgacgct ggaggatgcc 
ttgtcgcacg ttaaagcacg tcgtgctgtg gccgcgccga atgtcaccgt attggaaaag 
gttcttcgta atcccttgtg a 
<210> SEQ ID NO 4 
<211> LENGTH, 506 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, C. merolae laforin Met 27 polypeptide 
<400> SEQUENCE, 4 
Met Ala Arg Ala Pro Ala Ala Asp Ser Ser Gly Ala Gln Ser Thr Pro 
1 5 10 15 
Ala Ala Arg Arg Ala Ser Glu Gly Val Ser Val Ala Glu Pro Pro Ser 
20 25 30 
Lys Pro Ala Ala Asp Ser Ser Gly Ala Gln Ser Thr Pro Ala Ala Arg 
35 40 45 
Arg Ala Ser Glu Gly Val Ser Val Ala Gly Pro Pro Ser Lys Pro Ala 
50 55 60 
20 
60 
120 
180 
240 
300 
360 
420 
480 
540 
600 
660 
720 
780 
840 
900 
960 
1020 
1080 
1140 
1200 
1260 
1320 
1380 
1440 
1500 
1521 
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21 
-continued 
Ala Asp Ser Ser Gly Ala Gln Ser Thr Pro Ala Ala Arg Phe Ala Ser 
65 70 75 80 
Glu Gly Val Ser Val Pro Glu Pro Pro Ser Lys Pro Ala Ala Asp Ser 
85 90 95 
Ser Gly Ala Gln Ser Thr Pro Ala Ala Arg Gly Ala Ser Glu Asp Ile 
100 105 110 
Ser Val Pro Gly Pro Pro Ser Asp Ile Ala Asp Thr Ile Ser Lys Asn 
115 120 125 
Asp Arg Ser Val Thr Pro Thr Ile Pro Thr Leu Phe Arg Val Tyr Cys 
130 135 140 
His Thr Glu Phe Gly Asp Ala Val Val Ala Ala Gly Ser His Asp Lys 
145 150 155 160 
Leu Gly Asn Trp Glu Pro Ala Lys Ala Leu Arg Leu Arg His Gln Cys 
165 170 175 
Gln Val Asp Thr Pro Phe Arg Asp Cys Trp Glu Gly Glu Val Asp Leu 
180 185 190 
Val Pro Glu Thr Ser Phe Glu Phe Lys Phe Val Arg Leu Ile Gly Gly 
195 200 205 
Asp Pro Gln Arg Ala Leu Trp Glu Thr Gly Pro Asn Arg Arg Ala Val 
210 215 220 
Ile Gln Arg Asn Ser Lys Asp Gly Cys Leu Ile Glu Val Glu Trp Glu 
225 230 235 240 
Arg Thr Arg Val Leu Phe Ser Ile Tyr Tyr Pro Thr Lys Glu Lys Gln 
245 250 255 
His Leu Cys Val Thr Gly Asp Leu Pro Glu Ile Gly Arg Trp Val Glu 
260 265 270 
Pro Gly Pro Val Pro Met Ala Leu Ser Thr Thr Glu Glu Arg Leu Glu 
275 280 285 
Thr Gly Gly Lys Gly Arg Arg Trp Ser Leu Thr Val Ser Val Pro Ser 
290 295 300 
Thr Val Gly Lys Phe Ala Tyr Arg Tyr Val Leu Val Asp Asp Asn Arg 
305 310 315 320 
Gln Gln Thr Ile Trp Glu Arg Glu Pro Asn Arg Tyr Ala Thr Leu Glu 
325 330 335 
Arg Ala Val Asn Gly Arg Leu Glu Cys Phe Asp Ala Asn Phe Val Ala 
340 345 350 
Ser Leu Glu Phe Asp Glu Ile Cys Pro Asp Ile Tyr Ile Gly Pro Tyr 
355 360 365 
Pro Gln Thr Pro Glu His Val Glu Met Met His Glu Ala Gly Ile Thr 
370 375 380 
Ala Val Leu Asn Leu Gln Thr Asp Glu Asp Phe Ala His Arg Ser Ile 
385 390 395 400 
Pro Trp Ser Thr Leu Met Glu Thr Tyr Thr Ala Leu Glu Met Gln Val 
405 410 415 
Ile Arg Cys Pro Ile Pro Asp Phe Asn Ala Glu Ala Leu Met Gln Leu 
420 425 430 
Leu Pro Asp Ala Val Arg Ala Leu Asp Ala Ala Leu Lys Ala Lys Arg 
435 440 445 
Val Val Tyr Val His Cys Thr Ala Gly Met Gly Arg Ala Pro Ala Val 
450 455 460 
Val Val Ala Tyr Leu Val Trp Arg Arg Gly Met Thr Leu Glu Asp Ala 
465 470 475 480 
Leu Ser His Val Lys Ala Arg Arg Ala Val Ala Ala Pro Asn Val Thr 
22 
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23 
-continued 
485 490 495 
Val Leu Glu Lys Val Leu Arg Asn Pro Leu 
500 505 
<210> SEQ ID NO 5 
<211> LENGTH, 1140 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, c. merolae laforin Ser157 fragment polypeptide 
<400> SEQUENCE, 5 
atgtcagtta ccccgaccat 
gacgcagttg ttgccgctgg 
ctgcgtctgc gccatcagtg 
gtggatctgg ttccggaaac 
ccgcagcgcg cactgtggga 
aaagatggct gcctgatcga 
tacccgacca aagaaaaaca 
tgggtcgaac cgggtccggt 
ggcggtaaag gtcgtcgctg 
gcctatcgtt acgttctggt 
aatcgctatg caacgctgga 
tttgtggctt ccctggaatt 
cagaccccgg aacatgtgga 
caaacggatg aagacttcgc 
acggcactgg aaatgcaagt 
atgcaactgc tgccggatgc 
gtttatgttc attgtaccgc 
gtttggcgtc gcggcatgac 
gttgccgccc cgaatgtgac 
<210> SEQ ID NO 6 
<211> LENGTH, 377 
<212> TYPE, PRT 
cccgacgctg ttccgtgttt 
ctcccatgat aaactgggta 
ccaagttgat accccgttcc 
gagttttgaa tttaaattcg 
aaccggtccg aaccgtcgcg 
agttgaatgg gaacgtacgc 
gcacctgtgt gttacgggcg 
gccgatggcg ctgtcaacca 
gtcgctgacc gtcagcgtgc 
cgatgacaac cgccagcaaa 
acgtgctgtc aacggtcgcc 
tgatgaaatc tgtccggaca 
aatgatgcac gaagcgggca 
ccatcgtagt atcccgtggt 
gattcgctgc ccgatcccgg 
agtgcgtgcc ctggacgcag 
gggcatgggt cgtgcaccgg 
gctggaagat gcgctgagcc 
ggtgctggaa aaagttctgc 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
attgtcacac cgaatttggc 60 
actgggaacc ggcaaaagct 120 
gtgactgttg ggaaggcgaa 180 
tccgtctgat tggcggtgac 240 
ctgtgattca acgcaatagc 300 
gcgtcctgtt ttctatctac 360 
acctgccgga aatcggtcgt 420 
cggaagaacg cctggaaacc 480 
cgtctacggt gggcaaattc 540 
ccatttggga acgtgaaccg 600 
tggaatgctt cgatgcaaat 660 
tttatatcgg tccgtacccg 720 
ttaccgccgt tctgaacctg 780 
ccaccctgat ggaaacctac 840 
attttaatgc ggaagccctg 900 
ccctgaaagc aaaacgcgtg 960 
ctgtcgtggt tgcgtacctg 1020 
acgtcaaagc ccgccgtgct 1080 
gtaacccgct gtaactcgag 1140 
<223> OTHER INFORMATION, C. merolae laforin Ser157 fragment polypeptide 
<400> SEQUENCE, 
Met Ser Val Thr Pro Thr Ile Pro Thr Leu Phe Arg Val Tyr Cys His 
1 5 10 15 
Thr Glu Phe Gly Asp Ala Val Val Ala Ala Gly Ser His Asp Lys Leu 
20 25 30 
Gly Asn Trp Glu Pro Ala Lys Ala Leu Arg Leu Arg His Gln Cys Gln 
35 40 45 
Val Asp Thr Pro Phe Arg Asp Cys Trp Glu Gly Glu Val Asp Leu Val 
50 55 60 
Pro Glu Thr Ser Phe Glu Phe Lys Phe Val Arg Leu Ile Gly Gly Asp 
65 70 75 80 
Pro Gln Arg Ala Leu Trp Glu Thr Gly Pro Asn Arg Arg Ala Val Ile 
24 
US 9,222,114 B1 
25 
-continued 
85 90 95 
Gln Arg Asn Ser Lys Asp Gly Cys Leu Ile Glu Val Glu Trp Glu Arg 
100 105 110 
Thr Arg Val Leu Phe Ser Ile Tyr Tyr Pro Thr Lys Glu Lys Gln His 
115 120 125 
Leu Cys Val Thr Gly Asp Leu Pro Glu Ile Gly Arg Trp Val Glu Pro 
130 135 140 
Gly Pro Val Pro Met Ala Leu Ser Thr Thr Glu Glu Arg Leu Glu Thr 
145 150 155 160 
Gly Gly Lys Gly Arg Arg Trp Ser Leu Thr Val Ser Val Pro Ser Thr 
165 170 175 
Val Gly Lys Phe Ala Tyr Arg Tyr Val Leu Val Asp Asp Asn Arg Gln 
180 185 190 
Gln Thr Ile Trp Glu Arg Glu Pro Asn Arg Tyr Ala Thr Leu Glu Arg 
195 200 205 
Ala Val Asn Gly Arg Leu Glu Cys Phe Asp Ala Asn Phe Val Ala Ser 
210 215 220 
Leu Glu Phe Asp Glu Ile Cys Pro Asp Ile Tyr Ile Gly Pro Tyr Pro 
225 230 235 240 
Gln Thr Pro Glu His Val Glu Met Met His Glu Ala Gly Ile Thr Ala 
245 250 255 
Val Leu Asn Leu Gln Thr Asp Glu Asp Phe Ala His Arg Ser Ile Pro 
260 265 270 
Trp Ser Thr Leu Met Glu Thr Tyr Thr Ala Leu Glu Met Gln Val Ile 
275 280 285 
Arg Cys Pro Ile Pro Asp Phe Asn Ala Glu Ala Leu Met Gln Leu Leu 
290 295 300 
Pro Asp Ala Val Arg Ala Leu Asp Ala Ala Leu Lys Ala Lys Arg Val 
305 310 315 320 
Val Tyr Val His Cys Thr Ala Gly Met Gly Arg Ala Pro Ala Val Val 
325 330 335 
Val Ala Tyr Leu Val Trp Arg Arg Gly Met Thr Leu Glu Asp Ala Leu 
340 345 350 
Ser His Val Lys Ala Arg Arg Ala Val Ala Ala Pro Asn Val Thr Val 
355 360 365 
Leu Glu Lys Val Leu Arg Asn Pro Leu 
370 375 
<210> SEQ ID NO 7 
<211> LENGTH, 831 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, C. merolae laforin Gly258 fragment 
<400> SEQUENCE, 7 
atgggctgcc tgatcgaagt tgaatgggaa cgtacgcgcg tcctgttttc tatctactac 60 
ccgaccaaag aaaaacagca cctgtgtgtt acgggcgacc tgccggaaat cggtcgttgg 120 
gtcgaaccgg gtccggtgcc gatggcgctg tcaaccacgg aagaacgcct ggaaaccggc 180 
ggtaaaggtc gtcgctggtc gctgaccgtc agcgtgccgt ctacggtggg caaattcgcc 240 
tatcgttacg ttctggtcga tgacaaccgc cagcaaacca tttgggaacg tgaaccgaat 300 
cgctatgcaa cgctggaacg tgctgtcaac ggtcgcctgg aatgcttcga tgcaaatttt 360 
gtggcttccc tggaatttga tgaaatctgt ccggacattt atatcggtcc gtacccgcag 420 
26 
accccggaac atgtggaaat 
acggatgaag acttcgccca 
gcactggaaa tgcaagtgat 
caactgctgc cggatgcagt 
tatgttcatt gtaccgcggg 
tggcgtcgcg gcatgacgct 
gccgccccga atgtgacggt 
<210> SEQ ID NO 8 
<211> LENGTH, 276 
<212> TYPE, PRT 
27 
gatgcacgaa gcgggcatta 
tcgtagtatc ccgtggtcca 
tcgctgcccg atcccggatt 
gcgtgccctg gacgcagccc 
catgggtcgt gcaccggctg 
ggaagatgcg ctgagccacg 
gctggaaaaa gttctgcgta 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
US 9,222,114 B1 
-continued 
ccgccgttct gaacctgcaa 480 
ccctgatgga aacctacacg 540 
ttaatgcgga agccctgatg 600 
tgaaagcaaa acgcgtggtt 660 
tcgtggttgc gtacctggtt 720 
tcaaagcccg ccgtgctgtt 780 
acccgctgta a 831 
<223> OTHER INFORMATION, C. merolae laforin Gly258 fragment polypeptide 
<400> SEQUENCE, 8 
Met Gly Cys Leu Ile Glu Val Glu Trp Glu Arg Thr Arg Val Leu Phe 
1 5 10 15 
Ser Ile Tyr Tyr Pro Thr Lys Glu Lys Gln His Leu Cys Val Thr Gly 
20 25 30 
Asp Leu Pro Glu Ile Gly Arg Trp Val Glu Pro Gly Pro Val Pro Met 
35 40 45 
Ala Leu Ser Thr Thr Glu Glu Arg Leu Glu Thr Gly Gly Lys Gly Arg 
50 55 60 
Arg Trp Ser Leu Thr Val Ser Val Pro Ser Thr Val Gly Lys Phe Ala 
65 70 75 80 
Tyr Arg Tyr Val Leu Val Asp Asp Asn Arg Gln Gln Thr Ile Trp Glu 
85 90 95 
Arg Glu Pro Asn Arg Tyr Ala Thr Leu Glu Arg Ala Val Asn Gly Arg 
100 105 110 
Leu Glu Cys Phe Asp Ala Asn Phe Val Ala Ser Leu Glu Phe Asp Glu 
115 120 125 
Ile Cys Pro Asp Ile Tyr Ile Gly Pro Tyr Pro Gln Thr Pro Glu His 
130 135 140 
Val Glu Met Met His Glu Ala Gly Ile Thr Ala Val Leu Asn Leu Gln 
145 150 155 160 
Thr Asp Glu Asp Phe Ala His Arg Ser Ile Pro Trp Ser Thr Leu Met 
165 170 175 
Glu Thr Tyr Thr Ala Leu Glu Met Gln Val Ile Arg Cys Pro Ile Pro 
180 185 190 
Asp Phe Asn Ala Glu Ala Leu Met Gln Leu Leu Pro Asp Ala Val Arg 
195 200 205 
Ala Leu Asp Ala Ala Leu Lys Ala Lys Arg Val Val Tyr Val His Cys 
210 215 220 
Thr Ala Gly Met Gly Arg Ala Pro Ala Val Val Val Ala Tyr Leu Val 
225 230 235 240 
Trp Arg Arg Gly Met Thr Leu Glu Asp Ala Leu Ser His Val Lys Ala 
245 250 255 
Arg Arg Ala Val Ala Ala Pro Asn Val Thr Val Leu Glu Lys Val Leu 
260 265 270 
Arg Asn Pro Leu 
275 
28 
<210> SEQ ID NO 9 
<211> LENGTH, 801 
<212> TYPE, DNA 
29 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
US 9,222,114 B1 
-continued 
<223> OTHER INFORMATION, C. merolae laforin Arg267 fragment 
<400> SEQUENCE, 9 
cgtacgcgcg tcctgttttc tatctactac ccgaccaaag aaaaacagca cctgtgtgtt 60 
acgggcgacc tgccggaaat cggtcgttgg gtcgaaccgg gtccggtgcc gatggcgctg 120 
tcaaccacgg aagaacgcct ggaaaccggc ggtaaaggtc gtcgctggtc gctgaccgtc 180 
agcgtgccgt ctacggtggg caaattcgcc tatcgttacg ttctggtcga tgacaaccgc 240 
cagcaaacca tttgggaacg tgaaccgaat cgctatgcaa cgctggaacg tgctgtcaac 300 
ggtcgcctgg aatgcttcga tgcaaatttt gtggcttccc tggaatttga tgaaatctgt 360 
ccggacattt atatcggtcc gtacccgcag accccggaac atgtggaaat gatgcacgaa 420 
gcgggcatta ccgccgttct gaacctgcaa acggatgaag acttcgccca tcgtagtatc 480 
ccgtggtcca ccctgatgga aacctacacg gcactggaaa tgcaagtgat tcgctgcccg 540 
atcccggatt ttaatgcgga agccctgatg caactgctgc cggatgcagt gcgtgccctg 600 
gacgcagccc tgaaagcaaa acgcgtggtt tatgttcatt gtaccgcggg catgggtcgt 660 
gcaccggctg tcgtggttgc gtacctggtt tggcgtcgcg gcatgacgct ggaagatgcg 720 
ctgagccacg tcaaagcccg ccgtgctgtt gccgccccga atgtgacggt gctggaaaaa 780 
gttctgcgta acccgctgta a 801 
<210> SEQ ID NO 10 
<211> LENGTH, 267 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, C. merolae laforin Arg267 fragment polypeptide 
<400> SEQUENCE, 10 
Met Arg Thr Arg Val Leu Phe Ser Ile Tyr Tyr Pro Thr Lys Glu Lys 
1 5 10 15 
Gln His Leu Cys Val Thr Gly Asp Leu Pro Glu Ile Gly Arg Trp Val 
20 25 30 
Glu Pro Gly Pro Val Pro Met Ala Leu Ser Thr Thr Glu Glu Arg Leu 
35 40 45 
Glu Thr Gly Gly Lys Gly Arg Arg Trp Ser Leu Thr Val Ser Val Pro 
50 55 60 
Ser Thr Val Gly Lys Phe Ala Tyr Arg Tyr Val Leu Val Asp Asp Asn 
65 70 75 80 
Arg Gln Gln Thr Ile Trp Glu Arg Glu Pro Asn Arg Tyr Ala Thr Leu 
85 90 95 
Glu Arg Ala Val Asn Gly Arg Leu Glu Cys Phe Asp Ala Asn Phe Val 
100 105 110 
Ala Ser Leu Glu Phe Asp Glu Ile Cys Pro Asp Ile Tyr Ile Gly Pro 
115 120 125 
Tyr Pro Gln Thr Pro Glu His Val Glu Met Met His Glu Ala Gly Ile 
130 135 140 
Thr Ala Val Leu Asn Leu Gln Thr Asp Glu Asp Phe Ala His Arg Ser 
145 150 155 160 
Ile Pro Trp Ser Thr Leu Met Glu Thr Tyr Thr Ala Leu Glu Met Gln 
30 
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31 32 
-continued 
165 170 175 
Val Ile Arg Cys Pro Ile Pro Asp Phe Asn Ala Glu Ala Leu Met Gln 
180 185 190 
Leu Leu Pro Asp Ala Val Arg Ala Leu Asp Ala Ala Leu Lys Ala Lys 
195 200 205 
Arg Val Val Tyr Val His Cys Thr Ala Gly Met Gly Arg Ala Pro Ala 
210 215 220 
Val Val Val Ala Tyr Leu Val Trp Arg Arg Gly Met Thr Leu Glu Asp 
225 230 235 
Ala Leu Ser His Val Lys Ala Arg Arg Ala Val Ala Ala Pro 
245 250 
Thr Val Leu Glu Lys Val Leu Arg Asn Pro Leu 
260 265 
What is claimed is: 
1. A non-native glucan phosphatase polypeptide compris-
ing the amino acid sequence as set forth in SEQ ID NO: 6, 8 
or 10. 
20 
2. The polypeptide of claim 1, wherein the polypeptide is a 25 
thermophile. 
3. The polypeptide of claim 2, wherein the polypeptide is 
stable at least at a 3.0 pH to about 8.0 pH. 
4. The polypeptide of claim 2, wherein the polypeptide is 
stable at least at a temperature of about 10° C. to about 75° C. 
240 
Asn Val 
255 
5. A method for processing starch, comprising: 
providing the thermophilic glucan phosphatase of claim 1; 
exposing a starch to the thermophilic glucan phosphatase; 
and 
collecting the starch that has been exposed to the thermo-
philic glucan phosphatase. 
6. The method of claim 5, further comprising, before the 
collecting step, exposing the starch to a kinase, an amylase, or 
both. 
* * * * * 
